CandlesenseCandlesense
BMY•benzinga•

Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer

Summary

EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained efficacy.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on March 14, 2025 by benzinga

← Back to BMY News
    Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer | BMY Stock News | Candlesense